Medical device manufacturing in India is set to enter a new shift as the government strengthens its push to build an export-oriented ecosystem
Biocon delivered a strong start to FY27 with a sharp rise in earnings. The company's Q1 profit jumped four times year-on-year, supported by steady biosimilars demand. Revenue also increased, reflecting healthy growth across its key business segments.
Quarterly Earnings took the spotlight after Pfizer reported better-than-expected second-quarter results. However, the company made it clear that its focus extends beyond one strong quarter.
Retatrutide Early Access has started for a limited group of patients before its expected FDA approval. Eli Lilly has launched an expanded access program for eligible adults with severe obesity.
Moderna has beaten Wall Street revenue estimates just days before a major US regulatory decision. The quarterly revenue surprise comes as the company prepares for the FDA's verdict on its flu vaccine.
Cancer drug development drives Glenmark’s next phase of global expansion, the company targets USD 600 million revenue from new oncology launches
Strong Business, Indegene, Q1 FY27, operating revenue, net profit, EBITDA, EBITDA margin, active clients, Gen AI, pharmaceutical services, healthcare technology, revenue growth
Patients with Heart Failure often need hospital visits when fluid builds up in the body. MannKind now wants to change that with its Autoinjector Pen technology. The company is developing a treatment that could replace IV infusions with a quick...
Indian drugmaker Alembic Pharma has expanded its US portfolio with USFDA approval for generic constipation treatment.
Relopduo has officially entered the Indian market. The launch marks another step in strengthening cancer treatment options.
, CDSCO.jpg)